Eli Lilly Pediatric EBGLYSS Data Strengthens Broader Immunology Growth Story [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly (NYSE:LLY) reported positive topline Phase 3 results for EBGLYSS (lebrikizumab) in pediatric patients with moderate to severe atopic dermatitis. The data support a potential label expansion into pediatric use, further building out Lilly's immunology and dermatology presence. This update extends the EBGLYSS story beyond adult indications and arrives as the company continues to invest in its broader pipeline. Eli Lilly, trading at around $985.08, has already delivered very large multi year returns, with the share price up 20.3% over the past year and more than tripling over three years. The company is widely associated with GLP 1 drugs, but this EBGLYSS news highlights additional areas where Lilly is active, particularly in immunology. For investors tracking NYSE:LLY, pediatric atopic dermatitis is a different but commercially relevant piece of the broade
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) was downgraded by HSBC Holdings plc from "hold" to "reduce". They now have a $850.00 price target on the stock.MarketBeat
- Ireland courts U.S. companies as taoiseach brings deals to Trump on St. Patrick's Day [Fortune]Fortune
- Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans [Yahoo! Finance]Yahoo! Finance
- Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? [Yahoo! Finance]Yahoo! Finance
- LYB names David Dennison as head of investor relations; Dave Kinney to retire [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/6/26 - Form PRE
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website